0001437749-26-015633
SEC filingPuma Biotechnology reported $44.8M in revenue for Q1 FY2026, with gross margin holding at 76.7%; however, operating income was negative ($3.8M) and net income was -$3.8M, reflecting continued investment in R&D while generating strong operating cash flow of $15.4M.
Revenue for Q1 FY2026 totaled $44.8M. As disclosed in Management’s Discussion and Analysis, this reflects a decrease compared to the prior year, primarily attributable to higher deductions for variable consideration—specifically government chargebacks and payor mix—partially offset by an increase in selling price. Gross profit was $34.4M, yielding a gross margin of 76.7%. This margin reflects consistent cost of sales against stable product volume and confirms the durability of pricing power and manufacturing efficiency.
Operating income was -$3.8M and net income was -$3.8M, resulting in diluted EPS of -$0.07. These results reflect the company’s continued investment in research and development, particularly in advancing alisertib. Management states it anticipates significant expenses in 2026 related to clinical trials, R&D, and commercialization efforts. Internal R&D expenses include payroll-related costs, CRO fees, consultant fees, and stock-based compensation; external R&D is similarly structured across clinical development activities.
Net cash provided by operating activities was $15.4M, and with zero capital expenditures, free cash flow equaled $15.4M. This strong operating cash flow generation occurred despite the operating loss, underscoring the efficiency of core commercial operations. The absence of capital expenditures reflects disciplined capital allocation, consistent with management’s stated flexibility to prioritize R&D or marketing initiatives based on strategic needs.
Management reiterates that substantial resources will continue to be deployed toward product development, clinical trials, and commercialization. The development of alisertib remains a central focus, with anticipated significant expenses throughout 2026. Additionally, external factors such as tariffs on imported pharmaceutical products and APIs — recently imposed under Section 232 — may influence future cost structures, though no quantified impact is disclosed in the authoritative packet.